Abbott Laboratories (ABT) is drawing fresh scrutiny after sales declines in its Nutrition business, new product launches and pricing moves, and early signs of recovering volumes, all while analysts grow more cautious
World Manufacturing Enriched Powders and RTDs market to reach new heights by 2035, driven by functional nutrition demand, aging demographics, and e-commerce expansion.
In Q1 2026, Abbott Laboratories reported a modest earnings beat, closed its US$21.00 billion Exact Sciences acquisition to expand in cancer diagnostics, and outlined a new volume-led Nutrition strategy after a 6%
/PRNewswire/ – ELSE NUTRITION HOLDINGS INC. (BABY) (BABYF) (0YL.F) (“Else” or the “Company”), today reported financial results for the 2026 first quarter ended…